All In Biotech

Drug Trial Radar · NCT04483375

Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects

A Randomized, Double-blinded, Placebo-controlled, Single Ascending Dose, Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetics of SCTA01 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Mar 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

33

Actual

Start

Jul 24, 2020

Primary completion

Nov 17, 2020

Study completion Nov 17, 2020

Sponsor

Lead sponsor
Sinocelltech Ltd.Industry
Sponsor type
Industry
First posted
Jul 23, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics of SCTA01(anti-SARS-CoV-2 monoclonal antibody) in Healthy Chinese Subjects.

Conditions

  • Coronavirus Disease 2019(COVID-19)

Interventions

  • SCTA01Biological

    recombinant humanized anti-SARS-CoV-2 monoclonal antibody

  • PlaceboOther

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity(DLT)Time frame: 7 days
  2. Maximal Tolerable Dose(MTD)Time frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing SHIJITAN Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.